Skip to main content
SpringerLink
Log in

HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis

  • Short Communication
  • Published:
Molecular Diagnosis & Therapy Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Background

Advances in knowledge about the metabolic pathways involved in the pathogenesis of psoriasis and related diseases have led to a search for new therapeutic targets and the development of new biological drugs. Several studies have focused on HLA-C*06 and investigated correlations between the genetic risk factors of psoriasis and clinical parameters such as the severity of the disease and the response to treatment.

Objective

Our objective is to share experience from our institution in the observation of two patients with severe chronic plaque psoriasis who were unresponsive to any anti-TNF-α treatment and only partially responsive to ustekinumab. The patients are carriers of a rare allele of HLA-C that occurs in Caucasians.

Methods

The patients with moderate-to-severe chronic plaque psoriasis, and candidates for biological therapy were typed for the HLA-C locus at high resolution via polymerase chain reaction sequence-specific oligonucleotide probes (PCR-SSOP) using a commercial kit (LAB®Type, One Lambda Inc., Canoga Park, CA, USA). The socio-demographic variables and clinical data were collected.

Results

In our cohort of 134 patients, only two showed the presence of the allele HLA-C*18:01. To our knowledge, a coincidence between HLA-C*18 and severe psoriasis in Caucasian patients has not previously been described. The fact that both of these patients showed the same clinical history (unresponsive to any anti-TNF-α treatment and partially responsive to ustekinumab) cannot be attributed to a random observation because HLA-C*18 is extremely rare in Europe. As a consequence, at this latitude, it probably indicates a severe disease for which the proper therapy has still not been identified.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–85.

    Article  CAS  PubMed  Google Scholar 

  2. Farley E, Menter A. Psoriasis: comorbidities and associations. G Ital Dermatol Venereol. 2011;146:9–15.

    CAS  PubMed  Google Scholar 

  3. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280–4.

    CAS  PubMed  Google Scholar 

  4. Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6:383–92.

    Article  PubMed  Google Scholar 

  5. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263–71.

    Article  CAS  PubMed  Google Scholar 

  6. Capon F, Munro M, Barker J, et al. Searching for the major histocompatibility complex psoriasis susceptibility. J Invest Dermatol. 2002;118:745–51.

    Article  CAS  PubMed  Google Scholar 

  7. Helms C, Saccone NL, Cao L, et al. Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. Hum Genet. 2005;118:466–76.

    Article  CAS  PubMed  Google Scholar 

  8. Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006;78:827–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Talamonti M, Botti E, Galluzzo M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013;169:458–63.

    Article  CAS  PubMed  Google Scholar 

  10. Chiu HY, Wang TS, Chan CC, et al. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis. Br J Dermatol. 2014;171:1181–8.

    Article  CAS  PubMed  Google Scholar 

  11. Talamonti M, Galluzzo M, Chimenti S, Costanzo A. HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: outcome and long-term follow-up. J Am Acad Dermatol. 2016;74:374–5.

    Article  CAS  PubMed  Google Scholar 

  12. Solberg OD, Mack SJ, Lancaster AK, et al. Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies. Hum Immunol. 2008;69:443–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Mack SJ, Cano P, Hollenbach JA, et al. Common and well-documented HLA alleles: 2012 update to the CWD catalogue. Tissue Antigens. 2013;81:194–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Testi M, Andreani M, Locatelli F, et al. Influence of the HLA characteristics of Italian patients on donor search outcome in unrelated hematopoietic stem cell transplantation. Tissue Antigens. 2014;84:198–205.

    Article  CAS  PubMed  Google Scholar 

  15. Picciani BL, Carneiro S, Sampaio AL, et al. A possible relationship of human leucocyte antigens with psoriasis vulgaris and geographic tongue. J Eur Acad Dermatol Venereol. 2015;29:865–74.

    Article  CAS  PubMed  Google Scholar 

  16. Vilches C, Bunce M, Sanz L, et al. Molecular cloning of two new HLA-C alleles: Cw*1801 and Cw*0706. Tissue Antigens. 1996;48:698–702.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Rome “Tor Vergata”, Viale Oxford 81, 00133, Rome, Italy

    M. Galluzzo, S. Chimenti & M. Talamonti

  2. Laboratory of Immunogenetics and Transplant Biology, IME Foundation at Tor Vergata University Hospital, Rome, Italy

    M. Andreani & M. Testi

Authors
  1. M. Galluzzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Andreani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Testi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Chimenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Talamonti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Galluzzo.

Ethics declarations

Conflict of interest

SC served as a consultant and speaker for Pfizer, AbbVie, and MSD. The other authors have no conflicts of interest to declare.

Funding

No sources of financial assistance were received to conduct the study described in the manuscript.

Ethical approval and informed consent

This study was conducted in accordance with the Helsinki Declaration. All patients gave written informed consent to draw a vial of blood for DNA analyses as approved by “Tor Vergata Ethics Committee” (Approval No. 20745, v. 25 Mar 2005).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Galluzzo, M., Andreani, M., Testi, M. et al. HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis. Mol Diagn Ther 20, 227–230 (2016). https://doi.org/10.1007/s40291-016-0199-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40291-016-0199-y

Keywords

Search

Navigation